Arvinas Q1 sales miss estimates on lower collaboration revenue from Pfizer

Arvinas

12/05/2026 12:12

Overview

U.S. biotech firm's Q1 revenue dropped sharply and missed analyst expectations

Q1 net loss and operating loss both narrowed, beating analyst estimates

Company highlighted FDA approval of VEPPANU, the first approved PROTAC therapy

Outlook

Company expects cash position to fund operations into the second half of 2028

Result Drivers

REVENUE DECLINE - Q1 revenue fell mainly due to lower collaboration revenue from Pfizer after changes to the VEPPANU development plan in 2025

LOWER OPERATING EXPENSES - Operating expenses decreased, mainly due to lower R&D and G&A costs, including reduced compensation and external expenses, especially in the vepdegestrant program

Company press release: ID:nGNX20KnJd

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Miss
$15.60 mln
$18.10 mln (12 Analysts)
Q1 Net Income
Beat
-$57.60 mln
-$61.55 mln (12 Analysts)
Q1 Operating income
Beat
-$63.80 mln
-$68.41 mln (13 Analysts)
Q1 Operating Expenses
$79.40 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", 8 "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Arvinas Inc is $16.00, about 65.6% above its May 11 closing price of $9.66

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)